Pacira | PCRX - Gross Profit On Sales

Stock Price
25.14
Daily Change
-0.27 -1.06%
Monthly
8.04%
Yearly
-6.54%
Q2 Forecast
23.99

Pacira reported $142.25M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Assertio Holdings USD 22.24M 970K Jun/2024
Astellas Pharma JPY 444.26B 12.55B Mar/2026
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Coherus Biosciences USD 8.7M 853K Dec/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
J&J USD 17.24B 642M Mar/2026
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 142.25M 11.34M Dec/2025
Perrigo USD 362.2M 14.9M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Supernus Pharmaceuticals USD 164.04M 15.23M Dec/2025
Teva Pharmaceutical Industries USD 2.11B 547M Mar/2026
Xeris Pharmaceuticals USD 72.15M 8.77M Dec/2025
Xoma 992K 846K Jun/2024
Zoetis USD 1.64B 73M Dec/2025